China Resources Double Crane: Subsidiary Obtains Drug Registration Certificates for Some Products
36Kr reports that China Resources Double Crane Pharmaceuticals has received drug registration certificates from the National Medical Products Administration for several of its subsidiaries' products. These include Liglitin Metformin Tablets (II), Progesterone Injection (II), and Vortioxetine Hydrobromide Tablets (II). Separately, Osun Electric announced the termination of a planned investment in a venture capital fund with Beijing Fangyuan Jinding Investment Management Co., Ltd., citing strategic development plans and project progress. AI